Keep up to date with the lastest news and events on ACS Biomarker.
13 December 2013, Maastricht
Molecular diagnostics frontrunner strengthens R&D capacity and opens new lab in Amsterdam Today, 13th December, marks the opening of ACS Biomarker BV’s new state-of-the-art biomarker laboratory. The lab is specifically equipped for the rapid validation of cardiovascular disease diagnostics. ACS Biomarker collaborates with leading European and Dutch research consortia in large-scale patient studies. The new lab facilitates analysing biomarkers in thousands of patient samples in a high-throughput setting. This lab and the world-class collaborations position ACS Biomarker on the forefront of molecular diagnostics in the cardiovascular field. The lead product in development is a single diagnostic and prognostic multi-biomarker test for heart failure.
31 October 2012, Maastricht (the Netherlands)
ACS Biomarker announced today that it has strengthened the organization to manage its participation in several European biomarker research collaborations and to accelerate the biomarker validation activities in its new state-of-the-art lab facility. ACS Biomarker BV is a Dutch biotechnology company focusing on the discovery, validation and commercialization of novel biomarkers that improve prognosis and management of cardiac disease.
20 May 2011, Amsterdam/Maastricht
ACS Biomarker B.V., a Dutch biotechnology company focused on the discovery, validation and commercialization of novel cardiovascular biomarkers announces the closing of a financing round. The investment is made by the Life Sciences Fund Amsterdam and Limburg Ventures. The funding will be used to further develop the product pipeline and discover novel biomarkers that improve diagnosis, prognosis and management of cardiac diseases.